Reshaping Asia's Healthcare with mRNA Innovation

The COVID-19 pandemic acted as both a challenge and a catalyst, serving as a testbed that fundamentally reshaped the biotechnology landscape across Asia and beyond. What emerged during this period was not just a breakthrough moment for mRNA, but the early foundation of a broader transformation that is still unfolding.

- Patrick Bergstedt

1. Building an mRNA Innovation Ecosystem: Lessons from COVID-19

COVID-19 underscored the transformative potential of mRNA technology. Decades of foundational research enabled the rapid deployment of mRNA vaccines during the pandemic, demonstrating how sustained scientific investment can translate into real-world impact when urgency demands it.

The emergence of an mRNA innovation ecosystem during this period enabled major advances across research and development, regulatory processes and clinical trial design. Governments, public health authorities, researchers, academic institutions, vaccine developers and regulators worked together to accelerate vaccine deployment without compromising safety or scientific rigour. This unprecedented level of collaboration laid the groundwork for future innovation around mRNA technologies.

2. Expanding a Comprehensive Respiratory Portfolio